二甲双胍联合生活方式干预对比单纯生活方式干预预防中国糖调节受损人群进展为糖尿病的安全性和有效性:多中心、开放标签、随机对照试验
在中国43家医院内分泌科开展的多中心开放标签随机对照试验中,1678例糖调节受损患者随机接受二甲双胍联合生活方式干预或单纯生活方式干预。中位随访2.03年,联合组糖尿病发病率为17.27/100人年,单纯组为19.83/100人年,联合组糖尿病发生风险降低17%(HR 0.83,95%CI 0.70-0.99;log-rank p=0.043)。联合组不良事件报告比例更高,主要因胃肠道不良事件增多,严重不良事件比例两组相似。
要点
- 二甲双胍联合生活方式干预较单纯生活方式干预降低糖调节受损人群糖尿病发生风险(HR 0.83,95%CI 0.70-0.99)。
- 联合组糖尿病发病率为17.27/100人年,单纯组为19.83/100人年,中位随访2.03年。
- 联合组不良事件报告比例更高,主要为胃肠道不良事件,严重不良事件比例两组相似。
核心结论
- 在中国糖调节受损人群中,二甲双胍联合生活方式干预较单纯生活方式干预进一步降低糖尿病发生风险,显示联合干预在预防进展为糖尿病方面具有额外获益且无新的安全性问题。
研究设计与样本
- 多中心、开放标签、随机对照试验,在中国43家综合医院内分泌科开展。
- 纳入18-70岁、BMI 21-32 kg/m2的糖调节受损(糖耐量受损或空腹血糖受损,或两者兼有)患者,按1:1计算机生成随机分配,区组随机区组大小4,按血糖状态、高血压及任何抗高血压药物使用分层。
- 共1678例参与者随机分配至二甲双胍联合生活方式干预组(n=831)或单纯生活方式干预组(n=847),并至少接受一次分配干预。
- 二甲双胍用法:前2周每日口服850 mg一次,后滴定至每日口服1700 mg(850 mg每日两次)。
- 主要终点为2年随访结束时新诊断糖尿病的发生率,采用全分析集和符合方案集分析。
主要发现
- 中位随访2.03年期间,二甲双胍联合生活方式干预组糖尿病发病率为17.27/100人年(95%CI 15.19-19.56),单纯生活方式干预组为19.83/100人年(95%CI 17.67-22.18)。
- 二甲双胍联合生活方式干预组较单纯生活方式干预组糖尿病发生风险降低17%(HR 0.83,95%CI 0.70-0.99;log-rank p=0.043)。
- 二甲双胍联合生活方式干预组报告不良事件的参与者比例高于单纯生活方式干预组,主要因胃肠道不良事件更多。
- 报告严重不良事件的参与者百分比两组相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Impaired glucose regulation (defined as either impaired glucose tolerance or impaired fasting glucose) is an important risk factor for the development of diabetes. We aimed to evaluate the safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing diabetes in Chinese participants with impaired glucose regulation. METHODS: We did a multicentre, open-label, randomised controlled trial at 43 endocrinology departments in general hospitals across China. Eligible participants were individuals with impaired glucose regulation (ie, impaired glucose tolerance or impaired fasting glucose, or both), men or women aged 18-70 years with a BMI of 21-32 kg/m2. Eligible participants were randomly assigned (1:1) via a computer-generated randomisation to receive either standard lifestyle intervention alone or metformin (850 mg orally once per day for the first 2 weeks and titrated to 1700 mg orally per day [850 mg twice per day]) plus lifestyle intervention. Block randomisation was used with a block size of four, stratified by glucose status (impaired fasting glucose or impaired glucose tolerance), hypertension, and use of any anti-hypertensive medication. Lifestyle intervention advice was given by investigators at all participating sites. The primary endpoint was the incidence of newly diagnosed diabetes at the end of the 2-year follow-up. Analysis was done using the full analysis set and per-protocol set. This study is registered with ClinicalTrials.gov, number NCT03441750, and is completed. FINDINGS: Between April, 2017, and June, 2019, 3881 individuals were assessed for eligibility, of which 1678 (43·2%) participants were randomly assigned to either the metformin plus lifestyle intervention group (n=831) or the lifestyle intervention alone group (n=847) and received the allocated intervention at least once. During a median follow-up of 2·03 years, the incidence rate of diabetes was 17·27 (95% CI 15·19-19·56) per 100 person-years in the metformin plus lifestyle intervention group and 19·83 (17·67-22·18) per 100 person-years in the lifestyle intervention alone group. The metformin plus lifestyle intervention group showed a 17% lower risk of developing diabetes than the lifestyle intervention alone group (HR 0·83 [95% CI 0·70-0·99]; log-rank p=0·043). A higher proportion of participants in the metformin plus lifestyle intervention group reported adverse events than in the lifestyle intervention alone group, primarily due to more gastrointestinal adverse events. The percentage of participants reporting a serious adverse event was similar in both groups. INTERPRETATION: Metformin plus lifestyle intervention further reduced the risk of developing diabetes than lifestyle intervention alone in Chinese people with impaired glucose regulation, showing additional benefits of combined intervention in preventing progression to diabetes without new safety concerns. FUNDING: Merck Serono China, an affiliate of Merck KGaA, Darmstadt, Germany. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.
引用
- Zhang L, Zhang Y, Shen S, et al. Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2023. PMID: 37414069. doi:10.1016/S2213-8587(23)00132-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。